ArticleProceedings of the National Academy of Sciences of the United States of America2022
Homologous recombination-deficient mutation cluster in tumor suppressor
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine : official journal of the American College of Medical Genetics · 2025Guideline
- Distinct functions of mammalian RAD51 paralogs in genome maintenance.Biochemical Society transactions · 2026Review
- Spatiotemporal regulation of DNA repair proteins between Golgi and nucleus maintains genome stability.The Journal of cell biology · 2026Article
- RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition.NAR cancer · 2026Article
- Structural insight into how RAD51 paralog exchange regulates RAD51 filament formation.Nature structural & molecular biology · 2026Article
- Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classification.EBioMedicine · 2026Article
- High-throughput mapping of 6,888bioRxiv : the preprint server for biology · 2026Article
- Cancer mutations in RAD51 and its paralogues.PloS one · 2026Article
- Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions.Nature communications · 2025Article
- Article
- The human Shu complex promotes RAD51 activity by modulating RPA dynamics on ssDNA.Nature communications · 2024Article
- Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches.JCO precision oncology · 2024Article
- HBV promotes its replication by up-regulating RAD51C gene expression.Scientific reports · 2024Article
- High-throughput PRIME-editing screens identify functional DNA variants in the human genome.Molecular cell · 2023Article
- RAD51 paralogs synergize with RAD51 to protect reversed forks from cellular nucleases.Nucleic acids research · 2023Article
- Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond.DNA repair · 2023Review
- Hot on RAD51C: structure and functions of RAD51C-XRCC3.Molecular oncology · 2023Article
- Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.Cancer research · 2023Article
- RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles.Nature communications · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 2 countries.
Rohit PrakashDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Yashpal RawalDepartment of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229.ORCID 0000-0001-9209-788X
Meghan R SullivanDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.ORCID 0000-0003-4304-0566
McKenzie K GrundyDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Hélène BretInstitute for Integrative Biology of the Cell, Université Paris-Saclay, CEA, CNRS, Gif-sur-Yvette, 91198 France.ORCID 0000-0003-2899-3625
Michael J MihalevicDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Hayley L ReinDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.ORCID 0000-0001-8939-3442
Jared M BairdDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.ORCID 0000-0002-2628-9485
Kristie DarrahDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Fang ZhangDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-6018-0790
Raymond WangDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Tiffany A TrainaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0003-3597-0050
Marc R RadkeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195.
Scott H KaufmannDepartments of Oncology and Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905.ORCID 0000-0002-4900-7145
Elizabeth M SwisherDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195.ORCID 0000-0003-2331-0434
Raphaël GuéroisInstitute for Integrative Biology of the Cell, Université Paris-Saclay, CEA, CNRS, Gif-sur-Yvette, 91198 France.ORCID 0000-0001-5294-2858
Mauro ModestiCancer Research Center of Marseille, CNRS, INSERM, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, 13273 France.ORCID 0000-0002-4964-331X
Patrick SungDepartment of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229.
Maria JasinDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.ORCID 0000-0002-7976-2379
Kara A BernsteinDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.ORCID 0000-0003-2247-6459
University of Pittsburgh · USMemorial Sloan Kettering Cancer Center · USCentre National de la Recherche Scientifique · FRThe University of Texas Health Science Center at San Antonio · USUniversity of Washington · USMayo Clinic · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0MYEAST DNA REPAIR GENES AND PROTEINS OF THE RAD52 GROUPR01ES007061 · NIEHS · YALE UNIVERSITY · PI Patrick Sung · 1995 to 2026
$9.4MHomology-directed repair: BRCA2 and RAD51 paralogsR35CA253174 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Maria Jasin · 2020 to 2026
$6.7MMechanisms of DNA Homology-directed Genome Repair and Tumor SuppressionR35CA241801 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SUNG, PATRICK · 2019 to 2025
$6.0MRAD51 paralog function in cancer predisposition and genome integrity R01ES031796 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BERNSTEIN, KARA A · 2021 to 2025
$2.2MDetermining the effects of RAD51C ovarian cancer variantsF31CA264889 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIN, HAYLEY · 2022 to 2023
$82kThe interplay between RAD51C sub-complexes during replication fork repairF31ES027321 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SULLIVAN, MEGHAN · 2017 to 2018
$71kNCI NIH HHS F31 CA264889NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R35 CA241801NCI NIH HHS R35 CA253174NIEHS NIH HHS F31 ES027321NIEHS NIH HHS R01 ES007061NIEHS NIH HHS R01 ES031796
Abstract
Mutations in homologous recombination (HR) genes, including
Indexed as
DNA-Binding ProteinsHomologous RecombinationOvarian NeoplasmsRad51 RecombinaseTumor Suppressor ProteinsAdenosine TriphosphateFemaleHumansMutationAdenosine TriphosphateDNA-Binding ProteinsRAD51C protein, humanRad51 RecombinaseTumor Suppressor ProteinsXRCC2 protein, humanDNA repairHomologous recombinationRAD51CRAD51 paralogVariants of unknown significance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.